National cost savings from an ambulatory program for low-risk febrile neutropenia patients in Australia
Michelle Tew A B E , Daniel Forster A , Benjamin W. Teh B C D and Kim Dalziel AA Centre for Health Policy, Melbourne School of Population and Global Health, 207 Bouverie Street, Carlton, Vic. 3053, Australia. Email: dpforster@gmail.com; kim.dalziel@unimelb.edu.au
B National Centre for Infections in Cancer, Peter MacCallum Cancer Institute, 305 Grattan Street, Melbourne, Vic. 3000, Australia. Email: Ben.Teh@petermac.org
C Department of Infectious Diseases, Peter MacCallum Cancer Institute, 305 Grattan Street, Melbourne, Vic. 3000, Australia.
D Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Institute, 305 Grattan Street, Melbourne, Vic. 3000, Australia.
E Corresponding author. Email: Michelle.Tew@unimelb.edu.au
Australian Health Review 43(5) 549-555 https://doi.org/10.1071/AH19061
Submitted: 13 March 2019 Accepted: 28 May 2019 Published: 17 September 2019
Abstract
Objective The management of low-risk febrile neutropenia (FN) patients through ambulatory programs has demonstrated comparative safety and effectiveness to in-patient strategies. However, there is limited evidence of benefits of changing practice, particularly on a national scale. The aim of this study was to estimate costs and benefits of the program over a 10-year time horizon.
Methods A comparative cost analysis from a health system perspective was performed, comparing costs and length of stay (LOS) of patients enrolled in an ambulatory program to a historical cohort who did not receive the program. Generalised linear models were used for analysis and bootstrapped to account for uncertainty. National data of identified FN admissions were used to inform future projections, with varying proportions of low-risk patients and eligibility for the ambulatory program.
Results The overall LOS for patients in ambulatory cohort was 1.9 days shorter (95% confidence interval (CI) 1.0–2.8 days), a 50% reduction in in-patient bed-days. Although patients in the ambulatory cohort incurred additional costs due to care received outside hospital (mean (± s.d.) A$828.03 ± 124.30), the mean total cost incurred remained substantially lower than that of the historical cohort (A$2979 lower; 95% CI A$772–5391). On a national scale, this could translate into A$62.7 million in costs averted and 41 347 bed-days saved over 10 years if the low-risk prediction rate and eligibility for ambulatory programs remained at currently observed rates.
Conclusions The wider implementation of a safe and effective ambulatory program to manage low-risk FN patients can result in significant return-on-investment for the healthcare system by eliminating avoidable costs due to unnecessary lengthy hospital admissions.
What is known about the topic? There is strong evidence demonstrating out-patient treatment of low-risk FN patients to be an effective and cost-effective strategy compared with continued in-patient hospitalisation.
What does this paper add? This study demonstrates the sustainability of the ambulatory program in ensuring cost benefits and in-patient beds through real-life implementation data. It also provides evidence of the substantial cost and bed-days potentially averted when the cost savings and difference in LOS are estimated on a national scale over a 10-year time horizon.
What are the implications for practitioners? The management of low-risk FN patients through ambulatory or out-patient programs is a safe and effective approach. There is strong evidence demonstrating the likely cost savings and considerable bed-days saved, which can be reallocated to meet other medical demands.
Additional keywords: national projections.
References
[1] Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34 730–51.| 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.Crossref | GoogleScholarGoogle Scholar | 11850858PubMed |
[2] Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18 3038–51.
| The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients.Crossref | GoogleScholarGoogle Scholar | 10944139PubMed |
[3] Vidal L, Ben dor I, Paul M, Eliakim-Raz N, Pokroy E, Soares-Weiser K, Leibovici L. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database Syst Rev 2013; CD003992
| Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients.Crossref | GoogleScholarGoogle Scholar | 24105485PubMed |
[4] Vidal L, Paul M, Ben dor I, Soares-Weiser K, Leibovici L. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials. J Antimicrob Chemother 2004; 54 29–37.
| Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials.Crossref | GoogleScholarGoogle Scholar | 15201227PubMed |
[5] Carstensen M, Sorensen J. Outpatient management of febrile neutropenia: time to revise the present treatment strategy. J Support Oncol 2008; 6 199–208.
| 18551855PubMed |
[6] Cooksley T, Campbell G, Al-Sayed T, LaMola L, Berman R. A novel approach to improving ambulatory outpatient management of low risk febrile neutropenia: an Enhanced Supportive Care (ESC) clinic. Support Care Cancer 2018; 26 2937–2940.
| A novel approach to improving ambulatory outpatient management of low risk febrile neutropenia: an Enhanced Supportive Care (ESC) clinic.Crossref | GoogleScholarGoogle Scholar | 29675545PubMed |
[7] Ying FLM, Ping MCY, Tong M, Yan EYP, Yee TLS, Ting LY, Sim AL, Yu LC, Shiu BL, Kin AC. A cohort study on protocol-based nurse-led out-patient management of post-chemotherapy low-risk febrile neutropenia. Support Care Cancer 2018; 26 3039–3045.
| A cohort study on protocol-based nurse-led out-patient management of post-chemotherapy low-risk febrile neutropenia.Crossref | GoogleScholarGoogle Scholar | 29556814PubMed |
[8] Elting LS, Lu C, Escalante CP, Giordano SH, Trent JC, Cooksley C, Avritscher EB, Shih YC, Ensor J, Bekele BN, Gralla RJ. Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 2008; 26 606–11.
| Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia.Crossref | GoogleScholarGoogle Scholar | 18235119PubMed |
[9] Teuffel O, Cheng S, Ethier M, Diorio C, Martino J, Mayo C, Wing R, Sung L, Alibhai SM. Health-related quality of life anticipated with different management strategies for febrile neutropenia in adult cancer patients. Support Care Cancer 2012; 20 2755–64.
| Health-related quality of life anticipated with different management strategies for febrile neutropenia in adult cancer patients.Crossref | GoogleScholarGoogle Scholar | 22350594PubMed |
[10] Lingaratnam S, Worth LJ, Slavin MA, Bennett CA, Kirsa SW, Seymour JF, Dalton A, Koczwara B, Prince HM, O’Reilly M, Mileshkin L. A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment. Aust Health Rev 2011; 35 491–500.
| A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment.Crossref | GoogleScholarGoogle Scholar | 22126955PubMed |
[11] Teh BW, Brown C, Joyce T, Worth LJ, Slavin MA, Thursky KA. Safety and cost benefit of an ambulatory program for patients with low-risk neutropenic fever at an Australian centre. Support Care Cancer 2018; 26 997–1003.
| Safety and cost benefit of an ambulatory program for patients with low-risk neutropenic fever at an Australian centre.Crossref | GoogleScholarGoogle Scholar | 29018966PubMed |
[12] Teuffel O, Amir E, Alibhai S, Beyene J, Sung L. Cost effectiveness of outpatient treatment for febrile neutropaenia in adult cancer patients. Br J Cancer 2011; 104 1377–83.
| Cost effectiveness of outpatient treatment for febrile neutropaenia in adult cancer patients.Crossref | GoogleScholarGoogle Scholar | 21468048PubMed |
[13] Klastersky J, Paesmans M. The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer 2013; 21 1487–95.
| The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients.Crossref | GoogleScholarGoogle Scholar | 23443617PubMed |
[14] Innes HE, Smith D, O’Reilly S, Clark P, Kelly V, Marshall E. Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Br J Cancer 2003; 89 43–9.
| Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study.Crossref | GoogleScholarGoogle Scholar | 12838298PubMed |
[15] Hocking C, Taylor A, Hayward A. Early discharge and ambulatory care of low-risk patients with neutropenic fever in Australia. Intern Med J 2013; 43 591–5.
| Early discharge and ambulatory care of low-risk patients with neutropenic fever in Australia.Crossref | GoogleScholarGoogle Scholar | 23668271PubMed |
[16] Klastersky J, Paesmans M. Risk-adapted strategy for the management of febrile neutropenia in cancer patients. Support Care Cancer 2007; 15 477–82.
| Risk-adapted strategy for the management of febrile neutropenia in cancer patients.Crossref | GoogleScholarGoogle Scholar | 17294227PubMed |
[17] Freifeld A, Sankaranarayanan J, Ullrich F, Sun J. Clinical practice patterns of managing low-risk adult febrile neutropenia during cancer chemotherapy in the USA. Support Care Cancer 2008; 16 181–91.
| Clinical practice patterns of managing low-risk adult febrile neutropenia during cancer chemotherapy in the USA.Crossref | GoogleScholarGoogle Scholar | 17943327PubMed |
[18] Day E, Kim S, Hughes-Davies L. Barriers to protocol-led early discharge of low-risk febrile neutropenia patients. Clin Oncol 2014; 26 516
| Barriers to protocol-led early discharge of low-risk febrile neutropenia patients.Crossref | GoogleScholarGoogle Scholar |
[19] Lingaratnam S, Slavin M, Mileshkin L, Solomon B, Burbury K, Seymour J, Sharma R, Koczwara B, Kirsa SW, Davis ID, Prince M. An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009. Intern Med J 2011; 41 110–20.
| An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009.Crossref | GoogleScholarGoogle Scholar | 21272175PubMed |
[20] Independent Hospital Pricing Authority. National hospital cost data collection, public hospitals cost report, round 20 (financial year 2015–16). 2018. Available at: https://www.ihpa.gov.au/publications/national-hospital-cost-data-collection-public-hospitals-cost-report-round-20-0 [verified 1 August 2018].
[21] Austin PC, Rothwell DM, Tu JV. A comparison of statistical modeling strategies for analyzing length of stay after CABG surgery. Health Serv Outcomes Res Methodol 2002; 3 107–33.
| A comparison of statistical modeling strategies for analyzing length of stay after CABG surgery.Crossref | GoogleScholarGoogle Scholar |
[22] Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic evaluation in clinical trials. Oxford: Oxford University Press; 2014.
[23] Lingaratnam S, Thursky K, Slavin M, Kirsa S, Bennett C, Worth L. The disease and economic burden of neutropenic fever in adult patients in Australian cancer treatment centres 2008: analysis of the Victorian Admitted Episodes Dataset. Intern Med J 2011; 41 121–9.
| The disease and economic burden of neutropenic fever in adult patients in Australian cancer treatment centres 2008: analysis of the Victorian Admitted Episodes Dataset.Crossref | GoogleScholarGoogle Scholar | 21272176PubMed |
[24] Lingaratnam S, Mellerick A, Worth L, Green M, Guy S, Kirsa S, Slavin M, Renwick W, Filshie R, Thursky KA. Feasibility of early discharge strategies for neutropenic fever: outcomes of a Victorian organisational readiness assessment and pilot. Intern Med J 2013; 43 979–86.
| Feasibility of early discharge strategies for neutropenic fever: outcomes of a Victorian organisational readiness assessment and pilot.Crossref | GoogleScholarGoogle Scholar | 23809725PubMed |
[25] Australian Bureau of Statistics. 6401.0 – Consumer Price Index, Australia. 2018. Available at: http://www.abs.gov.au/ausstats/abs@.nsf/mf/6401.0 [verified 10 August 2018].
[26] Australian Government Department of Health. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (PBAC). 2016. Available at: https://pbac.pbs.gov.au/ [verified 10 August 2018].
[27] Australian Government Department of Health. Schedule of Pharmaceutical Benefits summary of changes effective 1 May 2017. 2017. Available at: http://www.pbs.gov.au/publication/schedule/2017/05/2017-05-01-general-soc.pdf [verified 3 August 2018].
[28] Australian Government Department of Health. Medicare Benefits schedule book operating from 01 May 2017. 2017. Available at: http://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/ED28842309B2CD13CA2580F7008294BE/$File/201705-MBS.pdf [verified 3 August 2018].
[29] AMA Victoria. Victorian public health sector medical specialists enterprise agreement 2013. 2013. Available at: https://northerndoctors.org.au/wp-content/uploads/2017/12/AMA-Vict-Public-Health-Sector-Medical-Specialists-Enterprise-Agreemenet-2013.pdf [verified 13 August 2018].
[30] AMA Victoria. Nurses and midwives (Victorian public health sector) (single interest employers) enterprise agreement 2016–2020. 2016. Available at: http://www.anmfvic.asn.au/~/media/files/ANMF/EBA%202016/Nurses-and-Midwives-Vic-PS-SIE-EA-2016-2020-amended [verified 13 August 2018].
[31] Dulisse B, Li X, Gayle JA, Barron RL, Ernst FR, Rothman KJ, Legg JC, Kaye JA. A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia. J Med Econ 2013; 16 720–35.
| A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia.Crossref | GoogleScholarGoogle Scholar | 23452298PubMed |
[32] Rolston KV. Neutropenic fever and sepsis: evaluation and management. In: Stosor V, Zembower T, editors. Infectious Complications in Cancer Patients. Cancer Treatment and Research, vol. 161. Cham: Springer; 2014. pp. 181–202.
